Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 earnings release for quarter ended June 30, 2026.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 earnings release for quarter ended June 30, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $783.3M, down 2%, while net income rose 8% to $333.0M
- Tyvaso DPI sales $326.6M, up 4%, offset by Nebulized Tyvaso down 18% to $126.0M
- Operating income $330.8M, down from $364.5M, reflecting higher cost of sales and R&D spending
- Ralinepag tablets and Nebulized Tyvaso IPF applications create potential approval catalysts by next year
- $500M remained available under the $2.0B repurchase authorization, with $1.5B ASR repurchases completed or settling
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.